Cargando…

Prognosis Prediction of CRAFITY Score in HCC Undergoing TACE Combined with PD-(L)1 Inhibitors and Molecular Targeted Therapy

BACKGROUND: The CRAFITY (C-reactive protein and alpha-fetoprotein in immunotherapy) score has demonstrated prognostic significance in hepatocellular carcinoma (HCC) patients undergoing immunotherapy. The study aimed to validate accuracy of CRAFITY score on predicting prognosis for patients with HCC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Ze-Xin, Xu, Xiao-Yang, Wang, Ze, Huang, Jin-Tao, Li, Wan-Ci, Zhang, Shuai, Shen, Jian, Zhong, Bin-Yan, Zhu, Xiao-Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676090/ https://www.ncbi.nlm.nih.gov/pubmed/38022730 http://dx.doi.org/10.2147/JHC.S439660

Ejemplares similares

Tumor SOCS3 methylation status predicts the treatment response to TACE and prognosis in HCC patients
por: Jiang, Bei-Ge, et al.
Publicado: (2017)

Efficacy of adjuvant TACE on the prognosis of patients with HCC after hepatectomy: a multicenter propensity score matching from China
por: Wu, Zhao, et al.
Publicado: (2023)

The Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC
por: Sun, Tao, et al.
Publicado: (2023)

The CRAFITY score can identify patients with hepatocellular carcinoma showing poor response to treatment with atezolizumab and bevacizumab
por: Lieb, Sabine, et al.
Publicado: (2023)

Prognostic significance of the CRAFITY score in hepatocellular carcinoma treated with immunotherapy: a systematic review and meta-analysis
por: Yang, Ming, et al.
Publicado: (2023)

Efficacy and safety of TACE combined with lenvatinib and PD‐1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study
por: Wang, Wei‐Jun, et al.
Publicado: (2023)

Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis
por: Yao, Man, et al.
Publicado: (2022)

Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS
por: Fan, Wenzhe, et al.
Publicado: (2021)

Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis
por: Bargellini, Irene, et al.
Publicado: (2021)

Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study
por: Jin, Zhi-Cheng, et al.
Publicado: (2023)

Recommendation of mHAP and ABCR scoring systems for the decision-making of the first and subsequent TACE session in HCC patients
por: Jia, Kefeng, et al.
Publicado: (2023)

Intra-arterial ethanol embolization augments response to TACE for treatment of HCC with portal venous tumor thrombus
por: Yang, Biao, et al.
Publicado: (2018)

Identifying optimal candidates for post-TIPS patients with HCC undergoing TACE: a multicenter observational study
por: Fan, Wenzhe, et al.
Publicado: (2022)

Identify optimal HAP series scores for unresectable HCC patients undergoing TACE plus sorafenib: A Chinese multicenter observational study
por: Zhu, Yejing, et al.
Publicado: (2023)

Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study
por: Lucatelli, Pierleone, et al.
Publicado: (2021)

The role of muscle depletion and visceral adiposity in HCC patients aged 65 and over undergoing TACE
por: Lim, Jihye, et al.
Publicado: (2021)

Changing TACTICS in intermediate HCC: TACE plus sorafenib
por: Radu, Pompilia, et al.
Publicado: (2020)

COCH predicts survival and adjuvant TACE response in patients with HCC
por: Wang, Chen, et al.
Publicado: (2021)

Effects of TACE combined with precise RT on p53 gene expression and prognosis of HCC patients
por: Liu, Yupeng, et al.
Publicado: (2018)

CT-radiomics and clinical risk scores for response and overall survival prognostication in TACE HCC patients
por: Bernatz, Simon, et al.
Publicado: (2023)

Correction to: Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study
por: Lucatelli, Pierleone, et al.
Publicado: (2021)

Circulating Levels of PAI-1 and SERPINE1 4G/4G Polymorphism Are Predictive of Poor Prognosis in HCC Patients Undergoing TACE()
por: Divella, Rosa, et al.
Publicado: (2015)

Evaluation of D-TACE combined with endovascular brachytherapy for HCC with MPVTT
por: Huang, Wei, et al.
Publicado: (2022)

Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis
por: Bettinger, Dominik, et al.
Publicado: (2018)

The Role of LDH Serum Levels in Predicting Global Outcome in HCC Patients Undergoing TACE: Implications for Clinical Management
por: Scartozzi, Mario, et al.
Publicado: (2012)

Volume–Function Analysis (LiMAx Test) in Patients with HCC and Cirrhosis Undergoing TACE—A Feasibility Study
por: Reichert, Matthias Christian, et al.
Publicado: (2020)

Development of TACE Refractoriness Scores in Hepatocellular Carcinoma
por: Chen, Li, et al.
Publicado: (2021)

The effect of lipiodol deposition in HCC after TACE on the necrosis range of PMCT
por: Sun, HongLiang, et al.
Publicado: (2017)

Hybrid Modelling of Transarterial Chemoembolisation Therapies (TACE) for Hepatocellular Carcinoma (HCC)
por: Perfahl, H., et al.
Publicado: (2020)

CXCL1 and CXCL6 Are Potential Predictors for HCC Response to TACE
por: Kinzler, Maximilian N., et al.
Publicado: (2023)

Preoperatively predicting early response of HCC to TACE using clinical indicators and MRI features
por: Li, Zhi-Wei, et al.
Publicado: (2022)

Published trials of TACE for HCC are often not registered and subject to outcome reporting bias
por: Grégory, Jules, et al.
Publicado: (2020)

Identifying the Best Anticancer Agent Combination in TACE for HCC Patients: A Network Meta-analysis
por: Guo, Tao, et al.
Publicado: (2018)

Combination Therapy of Sorafenib and TACE for Unresectable HCC: A Systematic Review and Meta-Analysis
por: Liu, Lei, et al.
Publicado: (2014)

DEB TACE for Intermediate and advanced HCC – Initial Experience in a Brazilian Cancer Center
por: Luz, Jose Hugo Mendes, et al.
Publicado: (2017)

Prognostic value of des-γ-carboxyprothrombin in patients with AFP-negative HCC treated with TACE
por: Sun, Hanyao, et al.
Publicado: (2022)

Low bone mineral density is a prognostic factor for elderly patients with HCC undergoing TACE: results from a multicenter study
por: Müller, Lukas, et al.
Publicado: (2022)

Quantitative washout in patients with hepatocellular carcinoma undergoing TACE: an imaging biomarker for predicting prognosis?
por: Müller, Lukas, et al.
Publicado: (2022)

Transarterial Chemoembolization (TACE) Combined with Sorafenib versus TACE Alone for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Study
por: Ren, Baosheng, et al.
Publicado: (2019)

A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE
por: Xia, Zicong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_krnuejvq5if38plamqli0shojg